Literature DB >> 16644744

18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI.

Heiko Schöder1, Diane L Carlson, Dennis H Kraus, Hilda E Stambuk, Mithat Gönen, Yusuf E Erdi, Henry W D Yeung, Andrew G Huvos, Jatin P Shah, Steven M Larson, Richard J Wong.   

Abstract

UNLABELLED: (18)F-FDG PET has a high accuracy in staging head and neck cancer, but its role in patients with clinically and radiographically negative necks (N0) is less clear. In particular, the value of combined PET/CT has not been determined in this group of patients.
METHODS: In a prospective study, 31 patients with oral cancer and no evidence of lymph node metastases by clinical examination or CT/MRI underwent (18)F-FDG PET/CT before elective neck dissection. PET/CT findings were recorded by neck side (left or right) and lymph node level. PET/CT findings were compared with histopathology of dissected nodes, which was the standard of reference.
RESULTS: Elective neck dissections (26 unilateral, 5 bilateral; a total of 36 neck sides), involving 142 nodal levels, were performed. Only 13 of 765 dissected lymph nodes harbored metastases. Histopathology revealed nodal metastases in 9 of 36 neck sides and 9 of 142 nodal levels. PET was TP in 6 nodal levels (6 neck sides), false-negative in 3 levels (3 neck sides), true-negative in 127 levels (23 neck sides), and false-positive in 6 levels (4 neck sides). The 3 false-negative findings occurred in metastases smaller than 3 mm or because of inability to distinguish between primary tumor and adjacent metastasis. TP and false-positive nodes exhibited similar standardized uptakes (4.8 +/- 1.1 vs. 4.2 +/- 1.0; P = not significant). Sensitivity and specificity were 67% and 85% on the basis of neck sides and 67% and 95% on the basis of number of nodal levels, respectively. If a decision regarding the need for neck dissection had been based solely on PET/CT, 3 false-negative necks would have been undertreated, and 4 false-positive necks would have been overtreated.
CONCLUSION: (18)F-FDG PET/CT can identify lymph node metastases in a segment of patients with oral cancer and N0 neck. A negative test can exclude metastatic deposits with high specificity. Despite reasonably high overall accuracy, however, the clinical application of PET/CT in the N0 neck may be limited by the combination of limited sensitivity for small metastatic deposits and a relatively high number of false-positive findings. The surgical management of the N0 neck should therefore not be based on PET/CT findings alone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16644744

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  51 in total

1.  The value of PET/CT to assess clinically negative necks.

Authors:  Enver Ozer; Barış Naiboğlu; Ryan Meacham; Cherie Ryoo; Amit Agrawal; David E Schuller
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-01-15       Impact factor: 2.503

2.  Contrast-enhanced CT and MRI for detecting neck metastasis of oral cancer: comparison between analyses performed by oral and medical radiologists.

Authors:  P T de Souza Figueiredo; A F Leite; F R Barra; R F Dos Anjos; A C Freitas; L A Nascimento; N S Melo; E N S Guerra
Journal:  Dentomaxillofac Radiol       Date:  2012-01-12       Impact factor: 2.419

3.  Combined PET/CT-perfusion in patients with head and neck cancers.

Authors:  Patrick Veit-Haibach; Daniel Schmid; Klaus Strobel; Jan D Soyka; Niklaus G Schaefer; Stephan K Haerle; Gerhard Huber; Gabriele Studer; Burkhardt Seifert; Thomas F Hany
Journal:  Eur Radiol       Date:  2012-07-08       Impact factor: 5.315

Review 4.  Present and future role of FDG-PET/CT imaging in the management of head and neck carcinoma.

Authors:  Kazuhiro Kitajima; Yuko Suenaga; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2015-10-27       Impact factor: 2.374

5.  [(18)F]-FDG PET/CT imaging for detection of nodal metastases in patients with squamous cell carcinoma of the pharynx and larynx: comparison with CT.

Authors:  Yuko Suenaga; Kazuhiro Kitajima; Tomonori Kanda; Naoki Otsuki; Ken-Ichi Nibu; Ryohei Sasaki; Tomoo Itoh; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2015-12-15       Impact factor: 2.374

Review 6.  Positron emission tomography for benign and malignant disease.

Authors:  Anthony Visioni; Julian Kim
Journal:  Surg Clin North Am       Date:  2011-02       Impact factor: 2.741

7.  PET/CT in head and neck cancer.

Authors:  Liselotte Højgaard; Lena Specht
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09       Impact factor: 9.236

8.  Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer.

Authors:  Michael Souvatzoglou; Matthias Eiber; Toshiki Takei; Sebastian Fürst; Tobias Maurer; Florian Gaertner; Hans Geinitz; Alexander Drzezga; Sibylle Ziegler; Stephan G Nekolla; Ernst J Rummeny; Markus Schwaiger; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-02       Impact factor: 9.236

9.  Cervical nodal metastasis in head and neck cancer: a clinical conundrum.

Authors:  Swaroop Revannasiddaiah; Ashwani Sood; Sudesh Kumar; Priyanka Thakur
Journal:  BMJ Case Rep       Date:  2013-11-06

10.  TNM staging with FDG-PET/CT in patients with primary head and neck cancer.

Authors:  Patrick Veit-Haibach; Christopher Luczak; Isabel Wanke; Markus Fischer; Thomas Egelhof; Thomas Beyer; Gerlinde Dahmen; Andreas Bockisch; Sandra Rosenbaum; Gerald Antoch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-24       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.